Dexamethasone sodium phosphate is under clinical development by Scilex Holding and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Dexamethasone sodium phosphate’s likelihood of approval (LoA) and phase transition for Back Pain took place on 28 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 28 Oct 2022 increased Dexamethasone sodium phosphate’s LoA and PTSR for Sciatica (Sciatic Pain).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexamethasone sodium phosphate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Dexamethasone sodium phosphate overview
Dexamethasone sodium phosphate (SEMDEXA) is under development for the treatment of Lumbosacral radicular pain (a type of chronic low back pain) and sciatica. The drug candidate is administered through epidural route. It is formulated as a gel. The drug candidate is a non-opioid steroid injectable without surfactants, preservatives or particulates.
Scilex Holding overview
Scilex Holding (Scilex) is a biopharmaceutical company that develop and commercialize non-opioid pain management solutions for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California, the US.
Quick View Dexamethasone sodium phosphate LOA Data
|Highest Development Stage|